Feedback PLC (LON:FDBK)

Feedback PLC (LON:FDBK)


Share Price
0.78 p
Change
-0.175 (-18.42 %)
Market Cap
£2.89 m
Proactive Investors - Run By Investors For Investors

Feedback PLC RNS Release

Feedback Medical CEO appointed Feedback plc CEO


RNS Number : 5008V
Feedback PLC
09 April 2019
 

Feedback plc

 

CEO of Feedback Medical appointed CEO of Feedback plc

 

Cambridge, UK, 9 April 2019 - Feedback plc (AIM: FDBK, "Feedback", or the "Company"), the specialist medical imaging technology company, has appointed Dr Tom Oakley as its Chief Executive Officer with immediate effect. This follows his appointment as CEO of its operating subsidiary, Feedback Medical Ltd on 14 February 2019. Dr Alastair Riddell will resume the role of Non-Executive Chairman of Feedback, the position he held prior to becoming Executive Chairman in July 2018.

 

As announced on 14 February 2019, Dr Oakley is a qualified medical doctor with experience in radiology. He has significant expertise in successfully launching healthcare products and helping small companies to realise and grow their market potential, particularly within the digital healthcare space. He also brings strong clinical and academic experience to the Company, having been an NHS England Clinical Entrepreneur Fellow since 2016. He received his Bachelor of Medicine with distinction from the University of Southampton.

 

Tom Oakley, CEO of Feedback plc, said:

 

"I look forward to taking on this expanded role. Since joining Feedback Medical, I have seen first-hand the potential within the Company's innovative technology. I plan to complete a full review of the business over the coming weeks, to develop a strategy which will maximise Feedback's market position, identify growth areas and review new potential market areas within digital imaging."

 

Alastair Riddell, Non-Executive Chairman of Feedback plc, said:

 

"Tom is already making an impact on the Company and we welcome him stepping up to become CEO of Feedback plc. As an able and ambitious entrepreneurial radiology doctor with a proven track record in developing innovative medical products, he understands the technology and is well placed to drive the Company forward, towards market expansion."

 

Option Grant

 

In conjunction with his appointment, Tom Oakley has today been granted 9,332,081 options over new ordinary shares in the Company ("Options") (representing approximately 2.5 per cent. of the Company's issued share capital) pursuant to the Company's Employee Share Scheme. The Options have an exercise price of 1.09 pence per Option and are exercisable at any time up to the tenth anniversary of the grant.

 

The FCA notification in respect of the Option grant, made in accordance with the requirements of the EU Market Abuse Regulation, is appended below.

 

AIM Rules Disclosures

 

Thomas James Oakley, aged 31, is or has been during the last five years, a director or partner of the following companies and partnerships:

 

Current directorships/partnerships

Past directorships/partnerships

·      Innovation Doctor Limited

 

·      Healthtech Check Ltd

·      Princes Castle Court Management Company Limited

·      Oakley Concepts Ltd

·      Locorum LLP

 

 

There is no further information required to be disclosed pursuant to Schedule 2(g) of the AIM Rules.

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Thomas Oakley 

2

Reason for the notification

a)

Position/status

Chief Executive Officer

 

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Feedback plc

 

b)

LEI

213800UGOF2GT2U2RV90 

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Options over ordinary shares of 0.25p each in Feedback plc

 

Identification code (ISIN) for Feedback plc ordinary shares:

GB0003340550

 

b)

Nature of the transaction

Grant of Options

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Exercise price of 1.09p

9,332,081

 

d)

Aggregated information

- Aggregated volume

- Price

N/A

e)

Date of the transaction

9 April 2019

 

f)

Place of the transaction

Outside a trading venue

 

 

 

 

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Lindsay Melvin, CFO

 

+44 (0)1954 718072

[email protected]

Allenby Capital Limited (Nominated Adviser)

David Worlidge / Asha Chotai

 

+44 (0)20 3328 5656

Peterhouse Corporate Finance Ltd (Joint Broker)

Lucy Williams / Duncan Vasey

+44 (0)20 7469 0936

Stanford Capital Partners Limited (Joint Broker)

Patrick Claridge / John Howes

+44 20 3815 8880

 

Instinctif Partners

Rozi Morris/ Deborah Bell/ Phillip Marriage

+44 (0)20 7457 2020

[email protected]


About Feedback plc

 

Feedback plc (AIM: FDBK) is a specialist medical imaging technology company providing innovative software and systems, through its fully-owned trading subsidiary, Feedback Medical Limited. Its products advance the work of radiologists, clinicians and medical researchers by improving workflows and giving unique insights into diseases, particularly cancer. Feedback Medical works with customers globally from headquarters in the internationally renowned scientific hub of Cambridge, UK. Its proprietary technologies are TexRAD®, the quantitative texture analysis tool and Cadran, a picture archiving communication system (PACS). For more information, see www.fbkmed.com/plc-landing-page

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCUWRBRKUASRAR

Feedback PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use